Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020; 22(11):E911-918. doi:
10.1001/amajethics.2020.911.
False information undermines health and exacerbates disabilities. Constitutional rights to free speech come with responsibilities. Clinicians and citizens have duties to counter false health information.
AMA J Ethics. 2021; 23(5):E432-433. doi:
10.1001/amajethics.2021.432.
The Domenici Wellstone Equitable Treatment Act sought to increase access to mental health care services and improve the efficiency and fairness of insurance coverage for mental illness.
A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.
Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”
An ethical case describes the use of a pharmacy's database to market directly to their patients without either patient consent or disclosure of the marketing intent of the materials they received.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.